Dealmaking Quarterly Statistics, Q3 2023

A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, July-September 2023

During Q3, biopharma merger and acquisition deal value reached $13.6bn and drew in $36.5bn in potential deal value from alliances. Device company M&A values reached $4.3bn, while in vitro diagnostics and research tools players’ M&A activity totaled $5.8bn.

Qstats Image 1
• Source: Alamy

Biopharma merger and acquisition value for the third quarter of 2023 reached $13.6bn from 33 transactions, 16 of which had disclosed values. Making up over half (54%) of that total was Biogen’s $7.3bn buy of Reata Pharmaceuticals. This deal and three other transactions were the only M&As to hit or exceed the billion-dollar mark during Q3 (see Exhibit 1).

The Biogen/Reata deal was the largest of the quarter and the third-highest M&A of the year so far (behind

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

More from In Vivo